X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

Researchers have developed a new and improved viral vector -- a virus-based vehicle that delivers therapeutic genes -- for use in gene therapy for sickle cell disease. In advanced lab tests using ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

Merck KGaA and subsidiary MilliporeSigma are doubling down on their gene therapy bets with a hefty nine-figure investment into expanded viral vector production. MilliporeSigma will spend $110 million ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University's College of Medicine and the UMass Chan Medical School have achieved ...

Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...

"Innovative Viral Vector Manufacturing and Technologies Drive Breakthroughs in Advanced Vaccines and Gene Therapies, Tackling ...

Gene therapy has provided treatment options for diseases that are beyond the reach of traditional approaches. Since 2016, between the European Medicines Agency (EMA) and the U.S. Food and Drug ...